Dr. Fitzgerald is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
350 Parnassus Ave
Ste 710
San Francisco, CA 94117Phone+1 415-665-1136Fax+1 415-665-8500
Education & Training
- University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 1976 - 1978
- HCA HealthONE/Sky Ridge Medical CenterResidency, Internal Medicine, 1973 - 1975
- HCA HealthONE /Presbyterian-St Luke’s Medical CenterInternship, Transitional Year, 1972 - 1973
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1972
Certifications & Licensure
- CA State Medical License 1976 - 2026
- CO State Medical License 1973 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Women's Health Castle Connolly, 2008
- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
- 5 citationsProteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-i...A Porzig, Katherine K. Matthay, Steven G. DuBois, Miguel Hernandez Pampaloni, Lloyd E. Damon
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 2012-05-15 - 85 citationsMetastatic pheochromocytoma and paraganglioma: focus on therapeutics.Pierre-François Plouin, P. Fitzgerald, Thereasa A. Rich, M. Ayala-Ramirez, Nancy D. Perrier
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 2012-02-07 - 90 citationsMalignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).P. A. Fitzgerald, Robert E. Goldsby, John P. Huberty, David C. Price, Randall A. Hawkins
Annals of the New York Academy of Sciences. 2006-08-01
Press Mentions
- Study Explores TMS Treatment for OCDOctober 8th, 2021
- 'Run for a Purpose' Breaks Stigma Surrounding Mental Health, Loved Ones Lost to SuicideMay 17th, 2021
- Story County Jail Releasing Non-Violent Offenders Amid COVID-19 OutbreakMarch 27th, 2020
- Join now to see all
Professional Memberships
- Member
- Member
- San Francisco Medical SocietyMember
- Member
- Pheochromocytoma and Paraganglioma Research Support Organization (PRESSOR)Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: